<DOC>
	<DOCNO>NCT02830763</DOCNO>
	<brief_summary>This study plan evaluate safety clinical efficacy medium-chain fatty acid capsule ( food-grade CNT-02 ) subject primary triglyceride deposit cardiomyovasculopathy ( TGCV ) neutral lipid storage disease myopathy ( NLSD-M ) associate adipose triglyceride lipase ( ATGL ) genetic defect .</brief_summary>
	<brief_title>Clinical Study Safety CNT-02 TGCV NLSD-M</brief_title>
	<detailed_description />
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<mesh_term>Lipid Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Ichthyosiform Erythroderma , Congenital</mesh_term>
	<criteria>1 . Patients ATGL gene deletion previously confirm . 2 . Patients take investigational product orally . 3 . Male female least 20 year old time consent . 4 . Patients give write informed consent . 1 . Patients diabetic ketoacidosis . 2 . Patients possibility diabetic ketoacidosis ( patient poorly control diabetes mellitus [ HbA1c &gt; 8.4 % , NGSP ] ) 3 . Patients terminal malignancy . 4 . Pregnant lactating woman . 5 . Patients consent use contraception participate study . 6 . Patients allergic MCT oil . 7 . Patients participate clinical trial . 8 . Otherwise , patient determine ineligible study investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>neutral lipid storage disease</keyword>
	<keyword>CNT-02</keyword>
	<keyword>primary triglyceride deposit cardiomyovasculopathy ( TGCV )</keyword>
	<keyword>neutral lipid storage disease myopathy ( NLSD-M )</keyword>
</DOC>